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Abstract
Background: In vitro and some in vivo studies suggested that genetic haplotypes may have an
impact on β2-agonist mediated airway responses in asthmatics. Due to strong linkage disequilibrium
the single nucleotide polymorphisms (SNPs) in the β2-adrenoceptor gene result in only a limited
number of haplotypes. We intended to evaluate the impact of β2-adrenoceptor haplotypes on β2-
agonist mediated airway responses and the development of tolerance in mild to moderate
asthmatics.
Methods: Patients were genotyped for the part of the β2-adrenoceptor gene with a known bearing
on receptor function and regulation. Cumulative dose response curves of fenoterol versus PD20
methacholine and FEV1 were constructed after 2 week treatment periods with either terbutaline
or placebo in a double blind, randomised and cross-over design. Analysis of the dose response
curves was based on a repeated measurement analysis of covariance.
Results: In our study population comprising 45 asthmatic patients, we found three limited allelic
haplotypes, resulting in six different genotypes. Our data support the existence of differences
between these six genotypes both in the shape of the dose response relationship of the β2-
adrenoceptor agonist fenoterol as well as in the propensity to develop tolerance for these effects
by pre-treatment with terbutaline. However, this could only be substantiated for the endpoint PD20
methacholine.
Conclusion: Between β2-adrenoceptor genotypes differences exist both in baseline β2-agonist
induced airway responses as well as in the propensity to develop tolerance during maintenance β2-
agonist therapy. The net differences after two weeks of therapy are, however, of magnitudes that
are unlikely to be of clinical significance.
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Background
Over the past decade an increasing number of single
nucleotide polymorphisms (SNPs) in the β2-adrenoceptor
(β2-AR) gene have been identified. Initially the focus of
research was on two highly prevalent non-synonymous
SNPs in the coding region of the gene that both result in
an amino acid substitution in the extra-cellular part of the
receptor protein: position 16 Arg→Gly and position 27
Gln→Glu. In vitro these amino acid changes appeared to
alter the susceptibility to receptor downregulation by
exposure to β2-agonists [1,2]. These observations fuelled a
number of clinical and in vitro/ex vivo studies yielding
inconsistent and sometimes conflicting results. Arg-16
was found to be associated with a greater acute bron-
chodilator response to a β2-AR agonist [3,4], but also with
loss of asthma control in some studies [5,6], but not in all
[7]. In an ex vivo study using human peripheral blood lym-
phocytes no impact of either polymorphism could be sub-
stantiated on baseline receptor expression or
responsiveness[8].
It is generally assumed that the in vivo consequence of the
downregulation of β2-ARs is tolerance towards the airway
smooth muscle mediated effects of β2 agonists. This toler-
ance has generally been difficult to show for the bron-
chodilator effects of β2-AR agonists, but is more
pronounced and potentially clinically relevant for their
bronchoprotective effects [9]. The relationship between
the polymorphic amino acids 16 and 27 and the suscepti-
bility to bronchodilator tolerance was the subject of two
clinical studies [10,11], but in only one of these such an
association could be substantiated [10]. Tolerance devel-
opment towards the bronchoprotective effects of β2-ago-
nists was the subject of two prospective clinical studies,
which did not find differences between amino acid 16
genotypes [12,13]. Results of in vitro studies using either
human mast cells or airway smooth muscle cells did not
aid in settling the issue [14,15].
More recently additional SNPs in the non-coding regula-
tory part of the β2-AR gene were described, some of which
affect receptor expression and regulation in vitro [16-18].
These SNPs are in strong linkage disequilibrium with
those coding for amino acid 27 in the β2-AR protein,
which results in only a very limited variation in extended
allelic haplotypes [16,18,19]. In vitro studies initially
focused on the SNPs in the 5' flanking region of the recep-
tor coding block in isolation. Analysis of the relative pro-
moter activities of serially truncated fragments of the 5'
flanking region suggested that the regulatory activity of
the β2-AR gene is largely concentrated in the region of 550
base pair 5' to the coding block. In particular, deletion of
the region containing the -367 SNP strongly reduced tran-
scription. In a comparative assay, alleles containing the -
367 T→ C mutation were shown to result in a lower tran-
scription rate (~17%) [18]. Recently, we were able to con-
firm this finding and showed that this was associated with
the decreased binding of an as yet unidentified transcrip-
tion factor [20].
The intronless coding region of the β2-AR protein is pre-
ceded by a small open reading frame encoding a 19 amino
acid peptide, the β2-AR upstream peptide (BUP), which
inhibits β2-AR mRNA translation [17]. The -47 C/T SNP
leads to a Cys → Arg substitution at position 19 of the
BUP. Transfection experiments with constructs containing
either variant of this SNP showed that Cys19 resulted in
an increase in receptor protein expression through an
effect on mRNA translation [16]. However, when the BUP
SNP was studied in the context of a validated haplotype,
the BUP Cys19 allele was associated with decreased recep-
tor protein and mRNA expression, which appeared to be
associated with a decreased bronchodilator response to an
inhaled β2-agonist in a cross-sectional study in a cohort of
asthmatics [19]. On the basis of this latter observation
these authors advocated studying the biological pheno-
typic consequences of the β2-AR SNPs only within the
context of validated haplotypes. In fact, our study extends
on this study. For our functional analyses we limited the
haplotypes to the SNPs in the 5'region of the gene, of
which an influence on transcription and regulation may
be expected, combined with the two far most prevalent
non-synonymous SNPs in the receptor protein coding
block at +46 and +79.
Our primary aim was to study the impact of different com-
binations of allelic haplotypes on tolerance to β2-agonist
induced bronchoprotection. To this end, we conducted a
double blind cross-over study of two-week treatment peri-
ods with either the short-acting β2-agonist terbutaline or a
matching placebo. Cumulative dose response curves of
the full β2-AR agonist fenoterol versus PD20 methacholine
were used as the main physiologic endpoint.
We found differences between six distinct β2-AR allelic
genotypes in the shape of the dose response relationship
and in the propensity to develop tolerance for these
effects. These differences are statistically significant and
functionally relevant only for bronchoprotection when
compared to bronchodilation in terms of recovery from
metacholine induced bronchoconstriction. The magni-
tudes of the net differences are, however, unlikely to be of
clinical significance
Methods
Patients
Recruitment of patients with mild to moderate asthma
and inclusion criteria have been described in detail else-
where [21]. According to current guidelines all patients
used inhaled corticosteroids, of which the dose was keptRespiratory Research 2006, 7:19 http://respiratory-research.com/content/7/1/19
Page 3 of 10
(page number not for citation purposes)
stable from at least 8 weeks prior to inclusion until the
end of the study. If inclusion criteria were met, a blood
sample was drawn for isolation of DNA. All subjects gave
written informed consent to participate in the study that
was approved by the Medical Ethics Committee of the
Academic Medical Centre in Amsterdam.
Design
The study had a randomized, placebo-controlled, double-
blind, cross-over design. Two treatment periods of two
weeks were preceded and separated by wash-out periods
of two weeks, during which all β2-agonists were discontin-
ued and only ipratropium bromide pressurized metered
dose inhaler (pMDI) was allowed for symptom relieve.
During the treatment periods a dry powder inhaler (Tur-
buhaler®, Astra-Zeneca, Zoetermeer, the Netherlands)
containing either 500 µg of terbutaline per inhalation or
placebo was used four times daily. The subjects attended
to the laboratory 24 hours after the last dose of study med-
ication and after ipratropium bromide had been withheld
for at least 8 hours. After baseline FEV1 and PD20 metha-
choline had been determined, subjects inhaled 200 µg of
fenoterol pMDI from an aerochamber as the first of a
series of 4 doubling doses, resulting in cumulative doses
of 200, 600, 1400, and 3000 µg respectively. One hour
after each dose of fenoterol a PD20 methacholine was
determined, immediately after which the next dose of
fenoterol was inhaled. Lung function measurements and
methacholine provocation tests were done as described
previously [21].
Assessment of extended β2-adrenoceptor genotypes
Genomic DNA was extracted from peripheral blood
mononuclear cells. Using allele-specific primers distin-
guishing between the -367T- and -367C-alleles, DNA was
amplified by PCR, applying standard conditions. The frag-
ment between nucleotides -367 and + 377 was amplified
using sense primers 7 or 8 (Table 1) and anti-sense primer
2, and the fragment between -367 and -1081 was ampli-
fied with anti-sense primers 215 or 216 and sense primer
214. The PCR products were separated by agarose gel elec-
trophoresis and isolated from the gel. Using the same -367
haplotype-specific primer sets, the sequence of the PCR
products was determined by automatic sequencing. In
case of -367 homozygous patients within the cohort stud-
ied, heterozygous polymorphisms downstream or
upstream were limited to the +46 SNP, thus still allowing
for the assessment of the full haplotypes.
Statistical analysis
Patients were divided into subgroups according to their
established allelic genotypes, based on combinations of
the three found limited allelic haplotypes I, II, and III.
FEV1 values are presented as % predicted, methacholine
provocation test results as (geometric mean) PD20 (µg).
Baseline FEV1 and PD20 are those measured after a two
week wash out period followed by a two week placebo
treatment period and before administration of the first
dose of fenoterol.
Because of the markedly skewed distribution of PD20 val-
ues, these were logarithmically transformed prior to anal-
ysis. Analysis of the dose response curves was based on a
repeated measurement analysis of covariance with
log(PD20) or FEV1 (% predicted) as dependent variable,
fenoterol dose, treatment (terbutaline vs. placebo), com-
bined allelic genotype and period as factors, baseline
log(PD20) or FEV1 respectively as a covariate and patient as
subject within whom repeated measurements may be cor-
related. An unstructured covariance matrix was used,
implying possible differences in SD's at the 8 different
fenoterol doses by treatment combinations, as well as var-
ying within-patient correlations between these 8 measure-
ments (heteroscedastic). In the model, all possible
interactions were allowed between the three factors fenot-
erol dose, treatment (terbutaline vs. placebo) and com-
bined allelic genotype. P-values were calculated from a
Wald-based F-test with denominator degrees of freedom
from the "within-between" method. The analysis com-
prised a total of 8 global model and 6 within-genotype
comparisons and associated P-values. Standard, P-values
were not adjusted for multiple comparisons.
For PD20 results (means and means ± SE's) from the anal-
yses were back-transformed to the normal scale. The sta-
tistical package SAS 8.2 was used for the calculations.
Table 1: Primers used for allele-specific PCR amplification and sequencing.
Primer Fragment direction Sequence
2 +396/+377 Antisense 5'-gtagcgatccactgcgatca-3'
7 -387/-367 Sense 5'-gggccccgcccgggccagcct-3'
8 -387/-367 Sence 5'-gggccccgcccgggccagccc-3'
214 -1081/-1061 Antisense 5'-ctgcaaattcctaaggagggc-3'
215 -349/-367 Antisense 5'-ctcgccctccttctcctga-3'
216 -349/-367 Antisense 5'-ctcgccctccttctcctgg-3'Respiratory Research 2006, 7:19 http://respiratory-research.com/content/7/1/19
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Results
Patient characteristics
A total of 50 patients were enrolled of whom 45 (11 male/
34 female), with a mean FEV1 of 84.6 % predicted, and a
geometric mean PD20 methacholine of 163 µg completed
the study. Two patients discontinued the study because of
side effects of the study medication (palpitations and
tremor). Two patients were excluded because of not
allowed use of β2-AR agonist as was one female patient
that turned out to be pregnant during the course of the
study.
The cohort of the 45 patients that completed the study
comprised 5 haplotypes within the part of the β2-AR gene
between nucleotides -1023 and + 79 (table 2), two of
which occurred only single, one of which (Ic) has not
been described previously. As described by others, linkage
disequilibrium was found between nucleotides -367 T/C,
-47 T/C (coding for Arg/Cys19 of the 5' leader peptide
(5'LP)), -20 T/C and + 46 A/G (coding for Glu/Gln27 of
the β2AR protein). This resulted in the presence within the
cohort of only 3 limited haplotypes with considerably dif-
ferences in (relative) frequencies (table 3). Baseline
patient characteristics of these combined limited allelic
haplotypes (or allelic genotypes) (table 3) as well as those
of the subgroups based upon the amino acid 16 and 27
polymorphisms displayed no statistically significant dif-
ferences.
Influence of the genetic polymorphisms and of terbutaline 
pre-treatment on the β2-agonist mediated effects on 
asthmatic airways
A. Bronchoprotection
Baseline PD20 methacholine values after placebo pre-
treatment as compared to terbutaline pre-treatment were
of a similar magnitude and not statistically different. Fig-
ure 1 shows the back-transformed means and SE's for
PD20 methacholine, estimated from the model described
above and corrected for baseline. There was no evidence
that the shape differences on the log-scale between the
dose-response curves for the two treatments vary between
the allelic genotypes (interaction: pre-treatment * fenote-
rol dose * genotype, P = 0.23). However, there was evi-
dence that the difference in PD20  between the two
treatments, averaged over fenoterol dose, is related to
allelic genotype (interaction: pre-treatment * genotype, P
= 0.0029) and also that the shape of the dose-response
curve, averaged over both treatments, varies between the
allelic genotypes (interaction: fenoterol dose * genotype,
P = 0.0011). No firm evidence was found that the relative
difference in PD20 between terbutaline pre-treatment and
placebo pre-treatment varies over the fenoterol dose
(interaction: pre-treatment * fenoterol dose, P = 0.071),
giving additional support for the averaging over fenoterol
dose. Averaged over fenoterol dose and genotype, terbuta-
line pre-treatment reduced PD20 compared to placebo pre-
treatment (P = 0.0026). Terbutaline pre-treatment
Table 2: Localization of SNPs and delineation of haplotypes of the β2-AR gene in the cohort. The limited haplotypes correspond to the 
SNPs in boldface. Haplotypes between brackets correspond to those of Drysdale et al.
Nucleotide: -1023 -654 -468 -367 -47 -20 46 79
Alleles G/A G/A C/G T/C T/C T/C G/A C/G
Limited Haplotype nF r e q u e n c y  ( % )
III Arg19Gly16Glu27 (2) A G G C C C G G 39 43,3
Ia Cys19Arg16Gln27 (4) G A C T T T A C 36 40
II Cys19 Gly16Gln27 (6) G A C T T T G C 13 14,4
Ib Cys19Arg16Gln27 (1) A G C T T T A C 1 1,1
Ic Cys19Arg16Gln27 (x) G G G T T T A C 1 1,1
Table 3: Frequencies and patient characteristics of the subgroups formed by the combined limited allelic hap1otypes. Baseline FEV1 
and PD20 were measured after a two week washout period followed by a two week placebo treatment period, before administration of 
the first dose of fenoterol.
Genotype Frequency Baseline FEV1 (% of 
predicted), mean (range)
Baseline PD20 geometric, 
mean (range)
Inhalation steroid dose, 
mean (range)
I/III 14 (31%) 85 (59 – 107) 141 (24 – 761) 470 (200 – 1200)
III/III 10 (22%) 86 (54 – 104) 313 (92 – 1240) 440 (200 – 1000)
II/III 5 (11%) 81 (72 – 99) 110 (20 – 371) 380 (200 – 500)
I/I 10 (22%) 85 (60 – 101) 176 (29 – 672) 530 (200 – 1000)
I/II 4 (9%) 82 (70 – 94) 74 (30 – 157) 500 (400 – 800)
II/II 2 (4%) 88 (82 – 93) 148 (33 – 668) 500 (200 – 800)Respiratory Research 2006, 7:19 http://respiratory-research.com/content/7/1/19
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reduced PD20 by 53% (95% CI: 31–68%, P = 0.0004) on
average for I/III patients and by 66% (95% CI: 35–82%, P
= 0.0019) for II/III patients (table 4). I/II patients showed
a comparable, but non-significant reduction. For the other
genetic groups, reductions are lower, if existing at all
(Table 4). Adjustment for multiple comparisons – by for
instance the Bonferroni correction – would not change
these conclusions qualitatively. After application of a
most conservative approach, i.e. by multiplying the
uncorrected P-values by 14, the highest significant P-value
of 0.0029 for the pre-treatment * genotype interaction
would still remain below the level of 0.05, namely 0.041.
For the within-genotype significant P-values for genotypes
I/III and II/III the values would become 0.0056 and
0.0154 respectively.
B. Recovery by fenoterol of methacholine induced 
bronchoconstriction
Figure 2 shows means and SE's for FEV1 measured one
hour after fenoterol inhaled directly after the previous
PD20 measurement, as estimated from the model and cor-
rected for baseline. There was no evidence that the shape
differences between the dose-response curves for the two
treatments vary between the allelic genotypes (interac-
tion: pre-treatment * fenoterol dose * genotype, P = 0.48).
Neither was there evidence that the difference in FEV1
between terbutaline pre-treatment and placebo pre-treat-
PD20 methacholine (mean ± SE) before and after cumulative doses of fenoterol in patients with different genotypes, pre-treated  with placebo or terbutaline for two weeks Figure 1
PD20 methacholine (mean ± SE) before and after cumulative doses of fenoterol in patients with different genotypes, pre-treated 
with placebo or terbutaline for two weeks. Averaged over treatment, the shape of the dose response curves varies between 
the genotypes (p = 0.0011). Averaged over fenoterol dose and genotype, terbutaline pre-treatment reduced PD20 compared to 
placebo pre-treatment (P = 0.0026). For the reductions in PD20 per genotype and associated p-values: see table 4. Drawn line: 
placebo pre-treatment, dashed line: terbutaline pre-treatmentRespiratory Research 2006, 7:19 http://respiratory-research.com/content/7/1/19
Page 6 of 10
(page number not for citation purposes)
ment varied over the fenoterol dose (interaction: pre-
treatment * fenoterol dose, P = 0.46), nor that the differ-
ence in FEV1 between the two treatments, averaged over
fenoterol dose, is related to allelic genotype (interaction:
pre-treatment * genotype, P = 0.29, see table 5). There was
weak evidence that the shape of the dose-response curve,
averaged over both treatments, varies between the allelic
genotypes (interaction: fenoterol dose * genotype, P =
0.060). There was some evidence that averaged over fenot-
erol dose and genotype terbutaline decreases FEV1 com-
pared to placebo (P = 0.027) by an estimated 1.58 (SE
0.68) percent points. Only for genotype I/I this decrease
reached statistical significance (see table 5). Adjustment
for multiple comparisons, by for instance the Bonferroni
correction, reduced all these findings to non-significance.
Discussion
This is the first study finding differences between β2-AR
genotypes in the shape of the dose response relationship
of β2-AR mediated airway effects in asthmatics in vivo. Our
data analysis, however, does not allow a further distinc-
tion in differences with respect to specific characteristics
of the dose response curves, such as the maximum effect
at infinite drug dose (Emax) or the dose at which 50% of
this maximum effect is obtained (ED50). We found no
evidence for an interaction between treatment and geno-
type influencing the shape of the dose response curve of
PD20 methacholine. Neither was there evidence that the
relative differences in PD20 after terbutaline pre-treatment
and placebo pre-treatment vary over the fenoterol dose, as
illustrated in figure 5. These latter two findings suggest
that, at least with respect to protection against metha-
choline induced bronchoconstriction, there is a genotype-
specific way by which binding of a β2-AR agonist to its
receptor translates into a clinical response as well as a gen-
otype specific but β2-agonist-dose-independent impact of
tolerance development on this response. The latter is illus-
trated by the parallel course of the two dose responses
curves within the different genotypes on semilogscale (fig-
ure 5).
The functional differences we observed between the allelic
genotypes cannot be explained by the known functional
consequences of individual SNPs or of haplotypes as
delineated in vitro. Moreover, the functional phenotype of
heterozygotic genotypes does not appear to fit in with that
of the homozygotic variants. For instance, in our study
genotypes I/I and III/III appear to be resistant to downreg-
ulation, while genotype I/III showed a significant degree
of downregulation for bronchoprotection by fenoterol.
Patients heterozygous on position 19 of the BUP and
position 27 of the β2-AR, genotypes I/III and II/III,
appeared to be most affected by desensitization, with
reductions in PD20 of 53 and 66%, respectively. This is in
line with a study that found more desensitization in
human airway smooth muscle cells derived from individ-
uals who were heterozygous on position 27 [15]. Our
findings illustrate why previous studies focusing on single
SNPs in the receptor protein coding block may have
yielded negative or even contradictory results. For exam-
ple, the sub-group of Gly-16 homozygotes consists of
three genotypes, III/III, II/III and II/II, with apparently dif-
ferent baseline β2-AR agonist mediated responses and pro-
pensities to develop downregulation. This implicates that
the results of functional studies based solely on variation
in amino acid 16 will depend upon the distribution of
genotypes within the subgroup of Gly-16 homozygotes.
The absence of a clear-cut relationship between genotypes
and functional phenotypes suggests the influence of other
yet unidentified co-factors. The identification of one such
factor may come from recent findings in mouse models
suggesting the existence of "cross-talk" in airway smooth
muscle between the β2-AR system and Gq-phospholipase
C coupled receptors responding to contractile agonists
such as methacholine [22]. The findings in this animal
model of an increase in cholinergic sensitivity in the
absence of chronic β2-AR stimulation and vice versa, fit in
with our observation of a combination of apparent resist-
ance to downregulation with respect to bronchoprotec-
tion (figure 1 and table 4) combined with the numerative
Table 4: The reduction in bronchoprotection by fenoterol after terbutaline pre treatment as compared to placebo pre treatment. The 
response was averaged over fenoterol dose 200–3000 µg. A 50% reduction corresponds to one double dose reduction of PD20 
methacholine. Negative numbers indicate an increase in response.
Reduction in PD20
Allelic genotype Median 95% CI P-value
I/III 53% 31% 68% 0.0004
III/III 22% -24% 50% 0.30
II/III 66% 35% 82% 0.0019
I/I -51% -139% 4% 0.078
I/II 50% -2% 76% 0.059
II/II 25% -106% 73% 0.58Respiratory Research 2006, 7:19 http://respiratory-research.com/content/7/1/19
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(and borderline significant) largest degree of loss of bron-
chodilation (figure 2 and table 5) within genotype I/I.
Since subjects of this genotype are homozygous Arg16/
Arg16, our data in this genotype agree with those of Israel
et al[6] who found an increased response to anti-choliner-
gic therapy in patients of this genotype when they were off
β2-agonist therapy, in combination with no improvement
in lung function when they were on β2-agonist therapy.
Some potential limitations of our study need to be dis-
cussed. Our active treatment arm consisted of the short
acting β2-agonist terbutaline, where long-acting β2-ago-
nists are nowadays the standard for maintenance bron-
chodilator therapy in asthma. What matters, however, is
whether the degree of "receptor stimulation" we obtained
is representative for the usual situation in maintenance
therapy. In this respect it is relevant that the dose of terb-
utaline we employed is generally considered to be about
therapeutically equivalent to the standard doses of the
two long-acting β2-agonists formoterol and salmeterol.
Furthermore, in a direct comparison 500 µg of terbutaline
induced a degree of bronchoprotective subsensitivity of a
same order of magnitude as the usually employed doses
of formoterol [23]. Using either formoterol or salmeterol
would also have limited the extent to which findings with
either of this drugs can be generalized in view of their dif-
ferences in intrinsic efficacy. Relevant in this respect may
be that in vitro [24] the intrinsic efficacy of terbutaline
appears to be in between those of salmeterol and formot-
erol. Next, the "test drug" we employed for the functional
FEV1 (mean ± SE) before and after cumulative doses of fenoterol in patients with different genotypes, pre-treated with placebo  or terbutaline for two weeks Figure 2
FEV1 (mean ± SE) before and after cumulative doses of fenoterol in patients with different genotypes, pre-treated with placebo 
or terbutaline for two weeks. FEV1 was measured one hour after fenoterol inhalation, directly after the previous PD20 meas-
urement. For the reductions in FEV1 per genotype and associated p-values: see table 5. Drawn line: placebo pre-treatment, 
dashed line: terbutaline pre-treatment.Respiratory Research 2006, 7:19 http://respiratory-research.com/content/7/1/19
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studies was fenoterol which is a full β2-AR agonist, like
formoterol, but unlike salbutamol, salmeterol and also
terbutaline that are partial agonists in vitro as well as in
vivo [21,25,26]. It cannot be ruled out that the responses
induced by fenoterol are stronger than those that would
have been induced by a partial agonist, but it is unlikely
that this would have changed the main conclusions of this
study. Furthermore, the cohort we studied was of a rela-
tively limited extent, especially in relation to the low num-
bers of individuals in some subgroups, particularly
genotype II/II, and to the uneven presence of the different
genotypes in asthmatic cohorts, as also noticed previously
[19]. This implicates that the functional implications of
especially genotype II/II need further study either in larger
groups of patients or after pre-selection of specific geno-
types.
Our genotype analyses contained all the SNPs with a
known bearing on gene regulation or receptor expression,
thus ignoring the three SNPs downstream from basepair
+79. In our opinion this is only of limited impact. The
SNPs at +252 and +523 are synonymous and so do not
result in amino acid substitution, while the one at + 491
is very uncommon. However it cannot be ruled out com-
pletely that these three SNPs have an impact on receptor
expression e.g. via an effect on mRNA stability.
Our study confirms that downregulation of β2-agonist
induced airway responses is more easily substantiated for
protection towards a bronchoconstrictive stimulus than
for bronchodilation form "baseline", in this case: recovery
form methacholine-induced bronchoconstriction one
hour earlier. This is in line with a recent study showing
that susceptibility to bronchodilator tolerance increases
when the degree of induced bronchoconstriction
increases [27]. The degree of tolerance development was
much less for FEV1 and at the most borderline statistically
significant for the cohort as a whole.
With respect to the potential clinical implications of our
findings it must be realised that for all genotypes some
degree of protection against bronchoconstriction
remained after two weeks of β2-agonist use. After terbuta-
line pre-treatment, the differences in the dose response
curves between genotypes were attenuated and the maxi-
mum difference in improvement in PD20 by the highest
dose of fenoterol between the genotypes (II/III versus I/I,
figure 1) was 1.5 doubling dose, where differences larger
than about one doubling dose are generally considered to
be clinically significant, in view of the confidence intervals
for repeated determinations of methacholine broncho-
provocation thresholds [28]. It is evident that at lower
doses of β2-agonist, such as normally used by asthmatics
in a clinically stable state, the differences are even smaller.
Altogether, this implicates that the functional phenotypi-
cal differences between the genotypes are probably only
of limited clinical significance, at least in stable mild to
moderate asthmatics as in our cohort. As we previously
argued, such differences are likely to be more relevant in
situations with a high state of functional antagonism,
such as in asthma exacerbations with severe bronchocon-
striction and functionally antagonized receptors by
inflammatory mediators, when high doses of short acting
β2-agonists are used [21].
Conclusion
Our data and analyses in a cohort of asthmatic patients
indicate differences between six distinct β2-AR allelic gen-
otypes in the shape of the dose response relationship of a
β2-AR agonist and in the propensity to develop tolerance
for these effects. The genotypes are based upon combina-
tions of three limited allelic haplotypes containing the
functionally relevant parts of the β2-AR gene. The differ-
ences we found are statistically significant and function-
ally relevant only for bronchoprotection when compared
to bronchodilation in terms of recovery from metha-
choline induced bronchoconstriction, and of a magnitude
unlikely to be of clinical significance.
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